Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery and services business, is pleased to announce that it has entered into a collaborative agreement with Infinity Pharmaceuticals, Inc. (Infinity), a cancer drug discovery company based in Cambridge, Mass. USA, to provide protein structure determination capabilities to accelerate Infinity’s drug discovery research. Sareum will utilise its skills in high throughput protein expression, purification and structure determination to illustrate the precise nature of how Infinity’s potential drug candidates interact with target receptor proteins. This detailed structural information will assist Infinity’s scientists in their search for new and improved cancer therapeutics by driving lead optimization results and providing co-complex structures for Infinity’s compounds. Financial terms of the agreement were not disclosed.

“We are delighted that Infinity has chosen Sareum as their partner in protein structure determination,” Commented Dr Tim Mitchell, Sareum's Chief Executive Officer. “This is our first protein structure determination collaboration in the United States and a significant first step into a very important market. We look forward to successful delivery of this project to Infinity and to closing additional partnerships such as this.”

Dr. Julian Adams, Infinity’s Chief Scientific Officer remarked: “Sareum’s protein structure determination technologies and expertise will enhance Infinity’s ability to design better, more robust molecules for the creation of new cancer treatments. This partnership further illustrates Infinity’s commitment to accelerate the discovery of novel therapeutics for patients suffering from cancer.”

For further information:

Sareum Holdings 01223 497700
Tim Mitchell, Chief Executive Officer

Buchanan Communications 020 7466 5000
Tim Anderson, Mary-Jane Johnson

Infinity Pharmaceuticals Inc 001 617 453 1000
Adelene Perkins, Chief Business Officer

Notes for editors:

About Sareum Holdings plc

 

Sareum Holdings plc is a specialist structure based drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer and to provide a range of drug discovery services to the pharmaceutical industry. Sareum's unique approach aims to halve the time it takes to discover new drug candidates.

Structure-based drug discovery involves the determination of a disease causing protein's three-dimensional structure. Once the structure is known, novel chemical entities are designed to 'lock-in' to the protein with the aim of reversing or arresting a disease's progression.

Sareum's approach to structure based drug discovery is to produce multiple recombinant proteins primarily through a baculovirus expression system; determine their structure using x-ray crystallography; and then use the Company's template-molecule x-ray screening technology to identify new chemical entities designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly synthesise further molecules and develop the most promising into potential drug candidates.

Sareum provides its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries. The Company aims to successfully deliver: Programmes for complete gene-to-candidate structure-based discovery; projects to accelerate or improve the productivity of specific activities; and drug candidates for licensing at the Phase I or Phase II clinical trials stage.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk

About Infinity Pharmaceuticals, Inc.

Infinity is a fully integrated, cancer drug discovery company focused on pathways of cancer cell survival. In addition, through select partnerships, Infinity's distinctive, proprietary collection of small molecules is being used against many of the world’s most important diseases. For more information, please visit the Infinity website at www.ipi.com